Introduction

!
Treatment outcomes of pancreatic ductal adenocarcinoma (PDAC), the most common malignancy of the pancreas, have improved little over recent decades [1] . This is at least partly due to the lack of suitable preclinical in vivo models [2] . Recently, researchers have been able to establish xenografts in immunodeficient mice by implanting patientderived tumor tissue obtained during surgery from various tumor types including PDAC. The main advantage of these xenografts is preservation of the original histological and genetic characteristics, even after consecutive passages. Additionally, these models have been shown to be predictive of clinical outcome and can be used for biomarker identification and personalized medicine [3] . However, large tissue quantities (10 -30 mm 3 ) are often needed to successfully generate patient-derived xenografts (PDXs), thereby limiting this technique to patients who are eligible for surgery [4] . As PDAC is usually diagnosed in a locally advanced setting, a substantial proportion of patients are excluded from curative surgery. Obtaining tumor material from these patients by an invasive procedure to generate xenograft models is irresponsible from a clinical perspective. Minimally invasive approaches that allow the establishment of xenografts at all clinical stages are urgently needed. In this pilot study we report the successful establishment of PDXs using fine needle biopsies (FNBs) obtained by endoscopic ultrasound (EUS) in patients with locally advanced disease.
Materials and methods
!
Collection of biopsy specimens Ethical approval
All procedures were approved by the Medical Ethical Committee (ML8713) and the Clinical Trial Center (S54185) of the University Hospitals of Leuven, Belgium in accordance with the most recent Helsinki Declaration. All patients provided signed informed consent for participation.
EUS-guided FNB specimens
Ten treatment-naive patients with a suspected malignant tumor of the pancreas on imaging were referred for EUS to obtain a tissue specimen for confirmation of carcinoma (• " Table 1) . After * These authors contributed equally.
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Background and study aim: Typically, pancreatic patient-derived tumor xenografts (PDXs) are established by transplanting large tumor biopsies obtained through invasive surgery approaches into immunocompromised mice. We aimed to develop pancreatic PDXs by transplanting tumor tissue acquired by endoscopic ultrasound (EUS)-guided fine needle biopsies (FNB), assess take rates compared to surgery-derived PDXs, and demonstrate the histological and genetic resemblance to the original tumor. Patients and methods: Biopsies of untreated pancreatic carcinoma were collected at surgery and during EUS and processed to generate PDXs.
Results: By centrifugation of FNB-derived tissue prior to engraftment, we achieved an engraftment rate of 60 % (6/10). Despite a decrease in stromal tissue, the general morphology of FNBderived PDXs was conserved as assessed by histopathology. At the genetic level, somatic mutation and copy number profiles were largely similar to the primary tumor. Conclusion: We show that it is technically feasible to establish pancreatic PDXs using a minimally invasive sampling technique, such as EUS-FNB. Although only a limited amount of tumor tissue was acquired, we obtained results similar to those from surgery-derived PDXs. 
Surgical biopsy specimens
Surgical biopsies from four patients with confirmed pancreatic adenocarcinoma and no evidence of locally advanced or metastatic disease were obtained at the time of tumor resection (• " Table 1). The surgical biopsy was placed in transport medium and prepared for engraftment.
Establishment of patient-derived PDAC xenografts
Female NMRI nude mice (aged 6 -8 weeks; Taconic, Denmark) were housed in individual ventilated cages in specific pathogenfree (SPF) conditions. All research procedures were executed in accordance with the applicable legal guidelines and under approval of the medical ethical committee for laboratory animals of the KU Leuven (P147 /2012).
To facilitate the FNB implantation, a tissue pellet was made by centrifugation (Eppendorf Centrifuge 5810 R) for 10 minutes at 1000 rpm. The interscapular fat pad of the mouse was externalized and a small pocket was created using an aseptic surgical technique. A small surgically resected tumor piece of 8 mm 3 was placed in the pocket or a tissue pellet obtained via EUS (1 -2 mm 3 ) was deposited with the support of a balloon pipet. Tumors were harvested as soon as their maximum volume reached 1000 -1500 mm 3 and were re-transplanted into the next generation (F1, F2, F3, F4, and F5). Engraftment time was defined as the time between pellet or biopsy implantation and tumor harvest at maximum volume. Tissue from each tumor was stored for histological analysis, molecular profiling, and cryopreservation.
Histology and immunohistochemistry
Hematoxylin and eosin (H&E) staining was performed on formalin-fixed paraffin-embedded (FFPE) tumor samples to assess the general tumor morphology including the pattern of growth, grade, and specific cyto-architectural characteristics. Immunohistochemistry (IHC) was performed on F1 and F3 tumors specifically to study the vascular composition of the stroma and to assess the overall preservation of the tumor phenotype.
High-throughput sequencing Whole-exome sequencing
Whole-exome sequencing (WES) was performed as described previously [5] . DNA libraries were prepared using the KAPA DNA Library Preparation Kit (KAPA Biosystems Inc.), after which exonic fragments were captured (SeqCap EZ Human Exome Library; Roche) and sequenced (HiSeq2000; Illumina) at a coverage > 30 × . Raw sequencing reads were mapped to both human (NCBI37 /hg19) and mouse (GRCm38 /mm10) reference genomes using Burrows -Wheeler Aligner (BWA) [6] and processed with the Genome Analysis Toolkit [7] . Exonic non-synonymous mutations with a coverage < 5 × (germline DNA) and > 10 × (primary or xenograft tumor) were selected. Cancer consensus genes described by Catalogue of Somatic Mutations in Cancer (COSMIC) were used to compare between primary and corresponding xenograft tumors [8] .
Whole-genome low-coverage (shallow) sequencing DNA was prepared using the KAPA DNA Library Preparation Kit (KAPA Biosystems Inc.) and sequenced at low coverage on a HiSeq2000. Raw sequencing reads were mapped to the human reference genome (NCBI37 /hg19) using BWA, revealing on average 5 897 670 mapped reads. Copy-number alterations (CNAs) were identified by QDNAseq v.1.0.5 by binning the reads in 100-kb windows [9] and segmenting the bin values by ASCAT v.2.0.7 [10] .
Targeted re-sequencing of KRAS and TP53
Xenografts with no matched germline DNA were analyzed for KRAS mutations using Sequenom MassArray [11] . TP53 mutations were detected using targeted re-sequencing. Amplicons for TP53 exons were amplified using PCR, subjected to KAPA DNA Library Preparation, and sequenced on a HiSeq2000 with a cover- 
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Statistics
All statistics were performed using SPSS Statistics v22 (IBM). Between-group differences in engraftment times were assessed using the Mann -Whitney U test. Spearman correlation coefficients were calculated to investigate the link between engraftment times and patient survival.
Results
!
Engraftment rates of PDXs derived from FNB and surgery
In this study, we included 14 pancreatic tumors. All tumor and PDX characteristics are summarized in • " Table1 and • " Table 2 . Overall, the engraftment rate was 71 % (10/14). All surgical samples were successfully engrafted (4/4), whereas an engraftment rate of 60 % (6/10) was observed for the FNBs. The average engraftment time for all biopsies was 17.9 weeks at F1 and 8.3 weeks at F3 (• " Table2). FNB-derived PDXs had a tendency towards faster engraftment at F1 (17.2 vs. 19 weeks; P = 0.67), a difference that became statistically significant at F3 (6.3 vs. 11.3 weeks; P = 0.02). Of note, there were progressive correlations between patient survival time and general engraftment time at F1 (r = 0.58; P = 0.1) and at F3 (r = 0.71; P = 0.03).
Preservation of tumor morphology and changes in the stromal component
At the histological level, the morphology, epithelial origin, and differentiation grade of all of the PDAC xenografts was maintained over the different transplant generations. No differences could be observed between xenografts derived from EUS (• " Fig. 1a ) and from surgery (• " Fig. 1b) , on either H&E staining or CK7 immunostaining (• " Fig. 1c) . The striking desmoplastic stromal reaction, evident in all original tumor biopsies via Masson Trichrome staining, disappeared in the first passage of the PDXs (• " Fig. 2a) . Human-derived fibroblasts were replaced with loosely arranged murine-derived fibroblasts as demonstrated by loss of human vimentin expression from F1 onwards (• " Fig. 2b ). In addition, tumor neovascularization by murine vessels, confirmed by anti-mouse CD31 staining, was already present in F1 (• " Fig. 2c ). The invasive character of the tumor, as indicated by perineural and local invasion into the adipose tissue and fascial planes, also included CK7-positive emboli in peritumoral lymphatic vessels and human vimentin expression in the neoplastic cells. The latter expression suggests activation of epithelial-to-mesenchymal transition (EMT); however, no distant metastases were detected.
Preservation of genetic alterations
When analyzing WES data for the F3 xenografts (n = 6), we observed on average 79 ± 27 somatic non-synonymous or stopgain mutations in each xenograft. Interestingly, we observed several mutations in genes known to be frequently mutated in PDAC, including KRAS, TP53, CDKN2A, and SMAD4 [13] . Because TP53 and KRAS are by far the most frequently mutated genes in PDAC, we assessed the mutation status of both of these genes in all of the other xenografts using targeted re-sequencing. By combining both WES and targeted sequencing data, we found that TP53 and KRAS were mutated in 60 % and 90 % of tumors, respectively. Among these, xenografts from surgery and from FNB both contained frequent mutations in KRAS (5/6 in FNB-derived vs. 4 /4 in surgery-derived xenografts; P > 0.05) and TP53 (3 / 6 for FNB-derived vs. 3/4 for surgery-derived xenografts; P > 0.05), which is similar to what has been observed by others [13] . . a A striking desmoplastic stromal reaction typically associated with pancreatic ductal adenocarcinoma is seen in an original surgical specimen (top image; patient identifier PAC005) but there is overall loss of the stromal component in the third passage of both the surgically derived xenograft (middle image; PAC005) and fine needle biopsy (FNB)-derived xenograft (bottom image: PAC004). b In addition to the general loss of stroma, the human vimentin-positive stroma present in the tumor of origin (top image; PAC003) disappears in consecutive passages of both the surgically obtained xenograft (middle image) and the FNB-derived xenograft (bottom image; PAC006) from F1 onward. c Immunohistochemical staining with murine-specific CD31 antibody shows that tumor neovascularization is essentially due to the mouse host, starting from the first generation onward in both the FNB-derived xenograft (upper image; PAC010) and the surgically derived xenograft (lower image; PAC001).
By profiling somatic copy number changes using low-coverage whole-genome sequencing and comparing between xenografts derived from FNB and from surgery, we found that the average ploidy was 2.7 ± 0.9 and 2.8 ± 0.8, respectively. We observed an almost identical number of breakpoints (57 ± 12 for FNB-derived vs. 54 ± 17 for surgery-derived xenografts) and percentage of the genome affected by copy number changes (59 ± 14 % for FNB-derived vs. 57 ± 20 % for surgery-derived xenografts). When comparing CNAs between primary tumors and surgeryderived xenografts, we found that 88 % (patient identifier PAC001), 67 % (PAC003), and 68 % (PAC005) of the genome had an equal copy number. Also CNAs affecting KRAS and TP53 were common, being found in seven and eight of the xenografts, respectively, with no difference between FNB-derived and surgery-derived PDXs (data not shown). Finally, we found that the majority of somatic mutations (n = 50) detected by WES in PAC005, in particular those affecting cancer consensus genes (n = 4), were present in both primary and xenograft tumors (• " Fig. 3) , and that only a limited number of mutations were present in only the primary tumor (n = 13) or xenograft (n = 19). Surgery-derived xenografts were therefore very similar in comparison to the original tumors when assessed by WES and copy number profiling.
Discussion
!
In this study we report the successful engraftment and establishment of PDX models using tissue obtained by EUS-guided FNB in patients with pancreatic carcinoma. To achieve this, we developed an engraftment protocol that included an additional centrifugation step allowing the implantation of a 22G EUS-acquired tissue micro-core. We showed successful engraftment in 60 % (6/ 10) of cases. This engraftment rate is similar to that described previously for surgical specimens [2, 14, 15] . To further explore the clinical relevance of PDXs established using FNB samples, we compared the tumor morphology from the first passage to the third using histology and immunohistochemistry. The specific PDAC PDX-related features, such as architecture and stromal content, were also confirmed in xenografts derived from FNBs [16] . Specifically, tumor morphology and differentiation grade were maintained upon propagation, while a general loss of stroma was observed, as was also demonstrated in surgically acquired PDAC PDXs and other tumor types. Human stroma was substituted by loose murine fibroblasts and vascular murine tissue from the first generation onwards [15] . The small differences in mutations and CNAs between primary tumors and xenografts that we observed are probably attributable to intra-tumor heterogeneity within the primary tumor and continued evolutionary pressure, which results in the accumulation of novel mutations in the xenografts. Overall, no obvious genetic differences were observed between the primary tumor and the xenografts from surgically derived biopsies, or between the xenografts derived from FNB and from surgery. Despite the limited number of PDXs, our data strongly suggest that FNB-derived xenografts bear similar genetic characteristics to their original primary tumor and may therefore be used, like surgically derived xenografts, in personalized medicine and drug development. Fig. 3 Genetic alterations between the primary tumor and xenograft for patient identifier PAC005. a Diagram of the somatic non-silent single nucleotide variants (SNVs) of PAC005. Blue circle, mutations from the primary tumor; red circle, mutations from the xenograft. Mutations common to both the primary tumor and xenograft are found in the center. Mutations found to be cancer consensus genes according to COSMIC are indicated in green. b Copy-number alterations (CNAs) in the primary tumor and xenograft for PAC005 obtained from whole-genome low-coverage sequencing. PAC005 was found to be diploid in the primary tumor but tetraploid in the xenograft. Because of this change in copy number, we compared the two samples by multiplying every copy number of the primary tumor by two. Centromeric regions are indicated as large red boxes below the figures, acrocentric chromosomes and heterochromatin (pericentric or telomeric) regions as small red boxes. The primary tumor and xenograft were compared by calculating the differences between them in copy number of each fragment. Fragments with an absolute difference of more than 0.5 are indicated in red. Threshold values of −0.5 and + 0.5 are indicated as dotted red lines.
